Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer

Song, Su Jeong; Min, Ji; Suh, Sung Yun; Jung, Sun Young; Hahn, Hyewon; Im, Seock Ah; Lee, Ju‐Yeun

doi:10.1007/s00520-017-3631-x

Cited by 69 publications

(70 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A prior study similarly reported physician-assessed CIPN toxicity grades that were lower than patientreported scores. 38 The findings of the current study corroborate other studies 2,3,8,39,40 reporting higher CIPN toxicity in patients treated with paclitaxel compared with docetaxel.…”

Section: Discussionsupporting

confidence: 89%

“…[41][42][43] In that literature, marital satisfaction, spousal support, and spousal responses to pain reportedly can contribute to psychological distress (depressive symptoms, anxiety symptoms, and mood disorders) which, in turn, is associated with pain dimensions, including symptom severity. 4,11,39,40,44 In the current study, a history of vigorous exercise prior to chemotherapy was not identified as a factor in the development of CIPN, although other studies have shown significantly reduced CIPN in women who were physically active prior to receiving chemotherapy. In our multivariable model, these quality-of-life measures were collected before, not after, neurotoxic chemotherapy was received.…”

Section: Discussioncontrasting

confidence: 51%

“…In the larger literature, the evidence regarding BMI and obesity is mixed. 4,11,39,40,44 In the current study, a history of vigorous exercise prior to chemotherapy was not identified as a factor in the development of CIPN, although other studies have shown significantly reduced CIPN in women who were physically active prior to receiving chemotherapy. 45,46 A strength of the current study is that patient reports of CIPN severity were collected prospectively throughout the duration of chemotherapy using toxicity reporting that is similar in structure and content to that of the PRO-CTCAE, which we believe now should be used for patient-reported symptom monitoring in both clinical trials and clinical practice.…”

Section: Discussioncontrasting

confidence: 51%

See 2 more Smart Citations

Patient‐reported and clinician‐reported chemotherapy‐induced peripheral neuropathy in patients with early breast cancer: Current clinical practice

Nyrop

Deal

Reeder-Hayes

et al. 2019

Cancer

View full text Add to dashboard Cite

BACKGROUND: In the current study, the authors investigated the incidence of moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) for chemotherapy regimens commonly used in current clinical practice for the treatment of patients with early breast cancer. Patient-reported and clinician-assessed CIPN severity scores were compared, and risk factors for CIPN severity were identified. METHODS: Patients completed a Patient-Reported Symptom Monitoring form and oncologists completed a Common Terminology Criteria for Adverse Events form. CIPN reports were collected prospectively during regularly scheduled infusion visits throughout the duration of chemotherapy. RESULTS: The sample included 184 women with a mean age of 55 years; approximately 73% were white. The 4 chemotherapy regimens used were doxorubicin and cyclophosphamide plus paclitaxel (60 patients); docetaxel and cyclophosphamide (50 patients); docetaxel, carboplatin, and anti-human epidermal growth factor receptor 2 (HER2) (24 patients); and doxorubicin and cyclophosphamide plus paclitaxel and carboplatin (18 patients). All patients treated with doxorubicin and cyclophosphamide plus paclitaxel and doxorubicin and cyclophosphamide plus paclitaxel and carboplatin received paclitaxel; all patients treated with docetaxel and cyclophosphamide and docetaxel, carboplatin, and anti-HER2 received docetaxel. The chemotherapy dose was reduced in 52 patients (28%); in 15 patients (29%), this reduction was due to CIPN. Chemotherapy was discontinued in 26 patients (14%), 8 because of CIPN. Agreement between patient-reported and clinician-assessed CIPN severity scores was minimal (weighted Cohen kappa, P = .34). Patient-reported moderate to severe CIPN was higher for paclitaxel (50%) compared with docetaxel (17.7%) (P < .001). Pretreatment arthritis and/or rheumatism (relative risk [RR], 1.58; 95% CI, 1.06-2.35 [P = .023]) and regimens containing paclitaxel (RR, 2.88; 95% CI, 1.72-4.83 [P < .0001]) were associated with higher CIPN severity. Being married (RR, 0.57; 95% CI, 0.37-0.887 [P = .01]) was found to be associated with lower CIPN severity. CONCLUSIONS: The discrepancy between patient-reported and clinician-assessed CIPN underscores the need for both patient and clinician perspectives regarding this common, dose-limiting, and potentially disabling side effect of chemotherapy. Cancer 2019;125:2945-2954.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussioncontrasting

confidence: 51%

Section: Discussioncontrasting

confidence: 51%

See 1 more Smart Citation

Patient‐reported and clinician‐reported chemotherapy‐induced peripheral neuropathy in patients with early breast cancer: Current clinical practice

Nyrop

Deal

Reeder-Hayes

et al. 2019

Cancer

View full text Add to dashboard Cite

show abstract

“…Patients with higher BMI, lower Patient-KPS scores, and lengthy regimens reported a significantly greater number of severe toxicities. The finding pertaining to BMI may reflect the association between obesity and higher symptom severity for chemotherapy-induced peripheral neuropathy that has been observed in prior studies [35][36][37][38][39].…”

Section: Resultsmentioning

confidence: 71%

Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer

et al. 2018

View full text Add to dashboard Cite

Background This study explores the incidence of patient‐reported major toxicity—symptoms rated “moderate,” “severe,” or “very severe”—for chemotherapy regimens commonly used in early breast cancer. Patients and Methods Female patients aged 21 years or older completed a validated Patient‐Reported Symptom Monitoring instrument and rated 17 symptoms throughout adjuvant or neoadjuvant chemotherapy. Fisher's exact tests compared differences in percentages in symptom ratings, and general linear regression was used to model the incidence of patient‐reported major toxicity. Results In 152 patients, the mean age was 54 years (range, 24–77), and 112 (74%) were white; 51% received an anthracycline‐based regimen. The proportion of patients rating fatigue, constipation, myalgia, diarrhea, nausea, peripheral neuropathy, and swelling of arms or legs as a major toxicity at any time during chemotherapy varied significantly among four chemotherapy regimens (p < .05). The mean (SD) number of symptoms rated major toxicities was 6.3 (3.6) for anthracycline‐based and 4.4 (3.5) for non‐anthracycline‐based regimens (p = .001; possible range, 0–17 symptoms). Baseline higher body mass index (p = .03), patient‐reported Karnofsky performance status ≤80 (p = .0003), and anthracycline‐based regimens (p = .0003) were associated with greater total number of symptoms rated major toxicities (alternative model: chemotherapy duration, p < .0001). Twenty‐six percent of dose reductions (26 of 40), 75% of hospitalizations (15 of 20), and 94% of treatment discontinuations (15 of 16) were in anthracycline‐based regimens. Conclusion Capturing multiple toxicity outcomes throughout chemotherapy enables oncologists and patients to understand the range of side effects as they discuss treatment efficacies. Continuous symptom monitoring may aid in the timely development of interventions that minimize toxicity and improve outcomes. Implications for Practice This study investigated patient‐reported toxicities for 17 symptoms recorded prospectively during adjuvant and neoadjuvant chemotherapy regimens for early breast cancer. An analysis of four commonly used chemotherapy regimens identified significant differences among regimens in both individual symptoms and total number of symptoms rated moderate, severe, or very severe. Longer chemotherapy regimens, such as anthracycline‐based regimens followed by paclitaxel, had higher proportions of symptoms rated major toxicities. The inclusion of patient perspectives on multiple toxicity outcomes at the same time at multiple time points during chemotherapy has the potential for improving patient‐provider communication regarding symptom management, patient satisfaction, and long‐term clinical outcomes.

show abstract

“…Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling side-effect, known to impair daily function and diminish quality of life [32]. Commonly used chemotherapeutic agents reported to cause neurotoxic effects include platinum derivatives, taxanes [40], vinca alkaloids, epothilones and newer agents (e.g thalidomide and bortezomib) [48]. The predominant sensory phenotype in patients treated with oxaliplatin or docetaxel is sensory loss affecting both upper and lower extremities.…”

Section: Introductionmentioning

confidence: 99%

Animal models of chemotherapy-induced peripheral neuropathy: a machine-assisted systematic review and meta-analysis

Currie

Angel-Scott

Colvin

et al. 2018

Preprint

View full text Add to dashboard Cite

Background and aims: Chemotherapy-induced peripheral neuropathy (CIPN) can be a severely disabling side-effect of commonly used cancer chemotherapeutics, requiring cessation or dose reduction, impacting on survival and quality of life. Our aim was to conduct a systematic review and meta-analysis of research using animal models of CIPN to inform robust experimental design. Methods: We systematically searched 5 online databases (PubMed, Web of Science, Citation Index, Biosis Previews and Embase (September 2012) to identify publications reporting in vivo CIPN modelling. Due to the number of publications and high accrual rate of new studies, we ran an updated search November 2015, using machine-learning and text mining to identify relevant studies. All data were abstracted by two independent reviewers. For each comparison we calculated a standardised mean difference effect size then combined effects in a random effects metaanalysis. The impact of study design factors and reporting of measures to reduce the risk of bias was assessed. We ran power analysis for the most commonly reported behavioural tests. Results: 341 publications were included. The majority (84%) of studies reported using male animals to model CIPN; the most commonly reported strain was Sprague Dawley rat. In modelling experiments, Vincristine was associated with the greatest increase in pain-related behaviour (-3.22 SD [-3.88; -2.56], n=152, p=0). The most commonly reported outcome measure was evoked limb withdrawal to mechanical monofilaments. Pain-related complex behaviours were rarely reported. The number of animals required to obtain 80% power with a significance level of 0.05 varied substantially across behavioural tests. Overall, studies were at moderate risk of bias, with modest reporting of measures to reduce the risk of bias. Conclusions: Here we provide a comprehensive summary of the field of animal models of CIPN and inform robust experimental design by highlighting measures to increase the internal and external validity of studies using animal models of CIPN. Power calculations and other factors, such as clinical relevance, should inform the choice of outcome measure in study design.

show abstract

Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer

Abstract: One-fifth of breast cancer patients who were treated with taxane-based chemotherapy experienced TIPN receiving treatment, and its risk factors were paclitaxel use, old age, overweight, and metastatic cancer.

Cited by 69 publications

References 25 publications

Patient‐reported and clinician‐reported chemotherapy‐induced peripheral neuropathy in patients with early breast cancer: Current clinical practice

Patient‐reported and clinician‐reported chemotherapy‐induced peripheral neuropathy in patients with early breast cancer: Current clinical practice

Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer

Animal models of chemotherapy-induced peripheral neuropathy: a machine-assisted systematic review and meta-analysis

Contact Info

Product

Resources

About